Prevention & lipidsCohort study
Strike early–strike strong lipid-lowering strategy with proprotein convertase subtilisin/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry
- Registry-based cohort study
- real-world
- AT-TARGET-IT registry
Authors' conclusion
Intensive and early lipid-lowering therapy using PCSK9i in patients with ACS (strike early-strike strong strategy) is safe and effective in clinical practice and associated with a reduction of residual CV risk.
Study context
- Population
- Patients with acute coronary syndrome (ACS) receiving PCSK9i prescription during hospitalization or at discharge, AT-TARGET-IT registry
- Participants
- 771 patients
- Outcome
- Patients reaching LDL-C target <55 mg/dL (lipid control outcome)
- Follow-up
- First lipid control
Main finding
As reported in the abstract
Achieved LDL-C target at first lipid control
527 (68.3%)
Median LDL-C at baseline (mg/dL)
137
Median LDL-C at first lipid control (mg/dL)
43
Of those at target, discharged on statin plus ezetimibe background therapy
404 (76.8%)
Observational data: associations, not effects.
Further findings
LDL-C · first lipid control
mg/dL
- Median LDL-C at baseline
- 137
- Median LDL-C at first lipid control
- 43
4P-MACE, 3P-MACE, all-cause mortality, ischaemia-driven revascularization by LDL-C quartile · median follow-up 11 months
- Stepwise lower risk in lower LDL-C quartile at first lipid control and in patients reaching LDL-C <55 mg/dL
- <23 mg/dL
Original publication
Summarised from the published abstract; every number is checked against it